A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) (SLE-BRAVE-X)

I4V-MC-JAIM -

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
1147
Trial Dates
Sep 9, 2019 - Apr 1, 2022
How long will I be in the trial?
The study will last about 156 weeks and may include up to 16 visits.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.